GANX Gain Therapeutics (GANX) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001819411
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
26
13F, latest reported quarter
Gain Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for Gain Therapeutics, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 50,000 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Chairman Islam Khalid bought about $50.0K of GANX on Aug 9, 2024; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 14,400 shares held after it.
- 1 other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CFO and Interim CEO Mack Gene bought about $14.5K of GANX on Aug 9, 2024; 1 other insider bought within 30 days and 26 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 25, 2022.
- +33.5% median (+30.9% mean) 90-day return after 4 previous buys.
- The trade is 1.8% of the 277,629 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RICHMAN ERIC I bought about $6.2K of GANX on Jul 1, 2024; 26 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on May 25, 2022.
- +33.5% median (+30.9% mean) 90-day return after 4 previous buys.
- The trade is 4.1% of the 289,629 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RICHMAN ERIC I bought about $14.5K of GANX on Jul 1, 2024; 26 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 30,000 shares held after it.
- No other insider bought within 30 days.
- 26 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Riley Jeffrey Scott bought about $115.8K of GANX on Mar 28, 2024, the largest insider purchase at the company on our record; 26 funds added in the latest 13F quarter.12 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
26 funds bought in last quarter
below 64% of Pharma & Biotech
Revenue
-58.4% year over year
below 82% of Pharma & Biotech
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
7.5% of the float short (float per yahoo 2026-10-27) · 6.5 days to cover · settled 2026-10-15
more than 61% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch GANX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-41.6%12M
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns GANX: institutional holders (13F)
13F holdings, latest reported quarter
1,923,546 sh
$3.9M
946,400 sh
$1.9M
566,130 sh
$1.1M
608,592 sh
$1.1M
480,269 sh
$974.9K
Congress trades in GANX
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
GANX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
GANX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Market Fund
$60.9K position · as of 2026-06-30
0.0%
iShares Micro-Cap ETF
$292.6K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$19.8K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$403.9K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$874.7K position · as of 2026-06-30
0.0%
Fidelity Nasdaq Composite Index Fund
$55.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 26 funds added last quarter. Each figure is a federal filing, dated the day it went public.
GANX financials
Revenue growth
-58.4%
XBRL, annual
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$55.2K
four quarters, 2023-01-01 to 2023-12-31
Revenue, TTM GANX
| FY Dec 2025 | $55.2K |
| FY Dec 2024 | $55.2K |
| FY Dec 2023 | $55.2K |
| FY Dec 2022 | $140.1K |
| FY Dec 2021 | $165.0K |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
revenue under $1M, the ratio says nothing
Net margin, TTM GANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM GANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -$18.9M |
| FY Dec 2022 | -$14.8M |
| FY Dec 2021 | -$12.5M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$3.5M |
| Sep 2024 | -$6.1M |
At each fiscal year end
Single quarter
Debt to equity
0.03x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity GANX
| FY Dec 2025 | 0.02x |
| FY Dec 2024 | 0.06x |
| FY Dec 2023 | 0.05x |
| FY Dec 2022 | 0.03x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | 0.03x |
| Mar 2026 | 0.03x |
| Dec 2025 | 0.02x |
| Sep 2025 | 0.07x |
| Jun 2025 | 0.12x |
| Mar 2025 | 0.07x |
| Dec 2024 | 0.06x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-55.14x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt GANX
| FY Dec 2025 | -46.05x |
| FY Dec 2024 | -43.04x |
| FY Dec 2023 | -33.22x |
| FY Dec 2022 | -24.35x |
| FY Dec 2021 | -17.81x |
| Jun 2026 | -55.14x |
| Mar 2026 | -51.86x |
| Dec 2025 | -46.05x |
| Sep 2025 | -40.77x |
| Jun 2025 | -40.87x |
| Mar 2025 | -44.69x |
| Dec 2024 | -43.04x |
| Sep 2024 | -42.64x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-268.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity GANX
| FY Dec 2025 | -155.7% |
| FY Dec 2024 | -205.0% |
| FY Dec 2023 | -141.6% |
| FY Dec 2022 | -65.5% |
| FY Dec 2021 | -67.7% |
| Jun 2026 | -268.3% |
| Mar 2026 | -214.7% |
| Dec 2025 | -155.7% |
| Sep 2025 | -261.7% |
| Jun 2025 | -240.2% |
| Mar 2025 | -290.2% |
| Dec 2024 | -205.0% |
| Sep 2024 | -263.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-159.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets GANX
| FY Dec 2025 | -115.4% |
| FY Dec 2024 | -132.8% |
| FY Dec 2023 | -104.3% |
| FY Dec 2022 | -55.8% |
| FY Dec 2021 | -57.2% |
| Jun 2026 | -159.2% |
| Mar 2026 | -139.9% |
| Dec 2025 | -115.4% |
| Sep 2025 | -153.1% |
| Jun 2025 | -128.1% |
| Mar 2025 | -159.7% |
| Dec 2024 | -132.8% |
| Sep 2024 | -150.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital GANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-232.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed GANX
| FY Dec 2025 | -135.2% |
| FY Dec 2024 | -186.1% |
| FY Dec 2023 | -132.3% |
| FY Dec 2022 | -63.0% |
| FY Dec 2021 | -63.0% |
| Jun 2026 | -232.0% |
| Mar 2026 | -183.7% |
| Dec 2025 | -135.2% |
| Sep 2025 | -212.1% |
| Jun 2025 | -199.3% |
| Mar 2025 | -251.6% |
| Dec 2024 | -186.1% |
| Sep 2024 | -236.7% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing GANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$37.4M
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value GANX
| FY Dec 2025 | $95.8M |
| FY Dec 2024 | $47.3M |
| FY Dec 2023 | $30.9M |
| FY Dec 2022 | $30.5M |
| FY Dec 2021 | $28.3M |
| Jun 2026 | $73.8M |
| Mar 2026 | $65.8M |
| Dec 2025 | $95.8M |
| Sep 2025 | $55.2M |
| Jun 2025 | $47.0M |
| Mar 2025 | $44.4M |
| Dec 2024 | $47.3M |
| Sep 2024 | $33.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield GANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -44.8% |
| FY Dec 2022 | -39.8% |
| FY Dec 2021 | -19.3% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing GANX
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | n/a | n/a | $55.2K | $140.1K |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M |
| EPS (diluted) | -0.61 | -0.89 | -1.71 | -1.48 |
| Operating cash flow | -$18.5M | -$18.9M | -$18.9M | -$14.7M |
| Cash | $20.8M | $10.4M | $11.8M | $7.3M |
| Long-term debt | $300.1K | $328.3K | $449.1K | $495.3K |
SEC XBRL, fiscal years, as known on 2026-10-28
GANX Stock Sonar score 5/7 axes
Find similar shapesCompareGANX ranks highest on risk and compliance (58th percentile) and financial health (39th), and lowest on profitability (12th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
